One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Author:
Funder
Bundesministerium für Gesundheit
Publisher
American Society for Clinical Investigation
Subject
General Medicine
Link
https://www.jci.org/articles/view/163657/files/pdf
Reference79 articles.
1. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
2. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
3. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial;Li;JAMA,2020
4. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (placid trial);Agarwal;BMJ,2020
5. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial;Journal of Infection;2024-09
2. Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial;2024-02-06
3. Early antibody treatment, inflammation, and risk of post-COVID conditions;mBio;2023-10-31
4. Treatable traits for long COVID;Respirology;2023-09-16
5. Covid-19 : encore une place pour le plasma de convalescent ? Focus sur les patients immunodéprimés;La Revue de Médecine Interne;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3